Phase 1CompletedINTERVENTIONAL
A Study of LY2189265 and Sitagliptin in Participants With Type 2 Diabetes
ClinicalTrials.gov · NCT01408888 · Registry updated: 2014-10-07
- Condition / research focus
- Diabetes Mellitus, Type 2
- Sponsor
- Eli Lilly and Company
- Countries with listed sites
- United States
- Registry dates and results
- Start: 2011-08. Completion: 2012-04 (may be estimated). Results are posted in this registry.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- LY2189265 (biological) — also listed as: Dulaglutide
- Sitagliptin (drug)
Where the study takes place — 3 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Daytona Beach, Florida, United States
Site recruitment: Not reported - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Honolulu, Hawaii, United States
Site recruitment: Not reported - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Dallas, Texas, United States
Site recruitment: Not reported